Avalo Therapeutics (AVTX) Return on Equity (2015 - 2026)

Avalo Therapeutics (AVTX) has 12 years of Return on Equity data on file, last reported at 0.01% in Q1 2026.

• For the quarter ending Q1 2026, Return on Equity fell 2.0% year-over-year to 0.01%; the trailing twelve-month figure through Mar 2026 stood at 0.01% (down 2.0% YoY), and the FY2025 full-year result was 0.01%, changed 0.0% from the prior year.
• Return on Equity for Q1 2026 stood at 0.01%, down from 0.01% in the prior quarter.
• Across five years, Return on Equity topped out at 0.03% in Q2 2023 and bottomed at 0.06% in Q3 2023.
• The 5-year median for Return on Equity is 0.0% (2025), against an average of 0.0%.
• The widest annual swing landed in 2023, when Return on Equity declined 6 bps; it then increased 4 bps in 2024.
• A 5-year view of Return on Equity shows it stood at 0.0% in 2022, then plunged by 17701 bps to 0.03% in 2023, then surged by 84 bps to 0.0% in 2024, then plunged by 97 bps to 0.01% in 2025, then retreated by 25 bps to 0.01% in 2026.
• The last three Return on Equity figures came in at 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025), per Business Quant data.

Peer Comparison